Biotechnology company developing small-molecule conditional inhibitors that modulate proteins in their functional state to selectively target oncogenic drivers
Biotechnology company developing small-molecule conditional inhibitors that modulate proteins in their functional state to selectively target oncogenic drivers. Its precision oncology programs include TEAD inhibitors for solid tumors and CDK2/CyclinE1 inhibitors, including for tumors resistant to CDK4/6 inhibitors.